Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 4Gemcitabine 3pembrolizumab 2pazopanib 2fludarabine 2cixutumumab 2brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Docetaxel 2Cyclophosphamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1tazemetostat 1sotigalimab 1soblidotin 1romidepsin 1reolysin 1perifosine 1pasireotide 1lorvotuzumab mertansine 1ixabepilone 1interferon gamma-1b 1exatecan 1durvalumab 1drozitumab 1atezolizumab 1Trastuzumab 1Trabectedin 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Synovial × drozitumab × Clear all
NCT00543712 2022-12-13

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Genentech, Inc.

Phase 2 Terminated
15 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡